Dakota Wealth Management Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Dakota Wealth Management boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,366 shares of the biopharmaceutical company’s stock after purchasing an additional 39 shares during the period. Dakota Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $973,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Adirondack Trust Co. boosted its holdings in shares of Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares during the last quarter. UMB Bank n.a. grew its position in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after acquiring an additional 10 shares during the period. Trust Co. of Vermont grew its holdings in Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 12 shares during the period. Nvwm LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 14 shares during the period. Finally, Moss Adams Wealth Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.6% in the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 15 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $675.79 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a market cap of $74.26 billion, a price-to-earnings ratio of 16.72, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The company’s 50-day moving average is $728.81 and its two-hundred day moving average is $940.38. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Wall Street Analyst Weigh In

A number of brokerages recently commented on REGN. Royal Bank of Canada lowered their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Bank of America restated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.